Eosinophilic Gastrointestinal Disease Program

Research & Innovation

The EGID team at Boston Children’s Hospital provides state-of-the-art care and participates in many leading-edge research projects. Our areas of research include:

Ongoing clinical trials

We are currently conducting several clinical trials for new medications to treat EoE and EGE. These new medications are innovative strategies to keep the eosinophils from being triggered and causing inflammation. For more information about our active enrolling clinical trials, ask our clinical team at your next appointment.

Selected publications

Below are some examples of key papers published by the EGID team.

Syverson, Erin Phillips MD; Rubinstein, Eitan MD, Real World Experience With Dupilumab in Eosinophilic Esophagitis in Children and Young Adults at a Tertiary Care Pediatric Medical Center, JPGN Reports: May 2022 - Volume 3 - Issue 2 - p e180
Syverson EP, Hait E, McDonald DR, Rubinstein E, Goldsmith JD, Ngo PD, Mitchell PD, Lee JJ. Oral viscous mometasone is an effective treatment for eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2020 Mar;8(3):1107-1109.
Rubinstein E, Hait EE, Mitchell PD, Lee JJ. Every-other-day Dosing of Oral Viscous Budesonide Is not Effective in the Management of Eosinophlic Esophagitis. J Pediatr Gastroenterol Nutr. 2018 Mar;66(3):395-397.
Rubinstein E, Lee JJ, Fried A, Logvinenko T, Ngo P, McDonald D, Hait EJ. Comparison of 2 delivery vehicles for viscous budesonide to treat eosinophilic esophagitis in children. J Pediatr Gastroenterol Nutr. 2014 Sep;59(3):317-20.

Contact the Eosinophilic Gastrointestinal Disease Program 617-919-9958

Fax 617-730-0496

International +1-617-355-5209

Email egid@childrens.harvard.edu

Eosinophilic Gastrointestinal Disease Program

Research & Innovation

Ongoing clinical trials

Selected publications

Contact Us